Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Portland VA Medical Center
With
GlaxoSmithKline
Schering-Plough
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 or older
diagnosis of hepatitis C
agree to participate in the study with written informed consent
plan to undergo treatment with Peg-IFN + Ribavirin
compensated liver disease (hemoglobin value \> 12 gm/dL for females or \> 13 gm/dL for males, WBC \> 3000/mm3, platelets \> 70,000/mm3, albumin \> 3.0 g/dL or within 20% of LLN, Serum creatinine \< 1.4 mg/dL, thyroid stimulating hormone within normal limits
confirmation from female patients that adequate contraception is being practiced during treatment period and for 6 months after discontinuation of therapy
confirmation from male patients that acceptable contraception is being practiced
You may not be if
hypersensitivity to IFN, RBV, or paroxetine
chronic liver disease other than chronic HCV
hemolytic anemia from any cause including hemoglobinopathies
evidence of advance liver disease
any preexisting medical condition that could interfere with participation in the protocol
evidence of cardiac ischemia, a significant unstable cardiac arrhythmia, heart failure, recent coronary artery surgery, uncontrolled HTN, unstable angina, or MI within past 12 months
clinically significant retinal abnormalities
substance abuse (must have abstained from abusing substance for at least 6 months)
diagnosis of major depression in the past 6 weeks
currently receiving full therapeutic dose of antidepressant medications
diagnosis of bipolar disorder
active psychotic condition
active delirium
pregnant female patients, men whose sexual partner is currently pregnant, and men and women who are not practicing adequate contraception
female patients who are actively breast feeding
patients with a known history of non-compliance with medical treatment
Clareo Health | Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine
